Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Company

Quibiotic SAS


Pépinière Genopole Entreprises
Campus 3 – 4 rue Pierre Fontaine
91000 EVRY-COURCOURONNES
Email: paolobonomi00@gmail.com
Tel: +33 (0)7 83 77 23 29

CEO: Paolo Bonomi
Quibiotic - Projet Shaker Quibiotic - Projet Shaker

#HealthTech #Innovative therapies

  • Innovation
  • Synthesis
  • Platforms
  • Beta-lactam ring
  • Anti-infectives

Domaine d'activité


Quibiotic develops three molecular synthesis platforms aimed at innovatively modifying β-lactam rings for new anti-infectives.

BACKGROUND
The roots of Quibiotic’s technology are to be found in an initial independent patent filed in 2016 by Paolo Bonomi. The base concept of the Quibiotic project is to reconsider lactam rings with the goal of developing novel therapeutics. In 2018, a second Italian patent was filed, in 2019, the project was selected for the Genopole Shaker program and in 2020 a third patent was filed. Thereafter, Quibiotic was officially created on 10 October 2021 by four associates with complementary competencies.

DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY

Quibiotic proposes three molecular synthesis platforms for the chemical modification of β-lactam rings in only three to four steps. The company’s technology makes it possible to link any given biologically active molecule to the β-lactam ring. Experimental trials have demonstrated class D β-lactamase inhibition activity for a first molecule and antineoplastic activity for a second one.

ACCOMPLISHMENTS / PARTNERSHIPS / HIGHLIGHTS

A project is currently underway in partnership with the University of Évry-Paris Saclay and Professor N. Jarroux at Lambe to study the complexation of different substrates with cyclodextrins. The goal of this work is to modulate the bioavailability or the activity of our novel compounds.
PARTNERSHIPS SOUGHT
We are actively seeking project partnerships with public and/or private institutions to empower the development of our platforms and to enable symbiotic relations with other technologies complementary to ours.

  • Further information

    3 patents

    Strengths
    Innovation in molecular synthesis strategies. Creation of a library of novel compounds. Simple chemical steps. Expertise in chemistry & biology + complementary competencies among the associates and an advisory board.

    Innovation assets
    A new way of thinking about β-lactam matrices.

    Other facts
    Passion, dedication and ethics.

Share
Genopole’s companies

#Industrial Biotech


In the same filed

Standing Ovation - Entreprise génopolitaine

STANDING OVATION

Standing Ovation is developing the production of casein via precision fermentation to enable non-animal-derived cheese and milk substitutes.

Discover
STH Biotech - Genopole's company

STH Biotech

STH BIOTECH is developing an innovative cannabis-based process for the reliable and sustainable production of active compounds for the well-being and healthcare sectors.

Discover
Synovance - entreprise généopolitaine

Synovance

Synovance has developed a revolutionary synthetic genomics platform for the conception of robust industrial bioproduction strains.

Discover
FABMID - entreprise génopolitaine

FABMID

We develop an in vitro manufactured targeted DNA vector to improve the efficiency of therapeutic cell transfection and to reduce the cost of gene-based therapies.

Discover
Proteinea - Genopole's company

Proteinea

Production as a service (PaaS) platform capable of producing recombinant proteins & enzymes cheaper and on a scale.

Discover
Altar - entreprise génopolitaine

Altar

Altar is a specialist in the conception and operation of automated fluidic continuous culture systems for adaptive laboratory evolution and the development of microbial strains for industry.

Discover
Yposkesi - Genopole's Company

Yposkesi

YposKesi is the first French company to develop and manufacture gene and cell therapy products for rare diseases.

Discover
Watchfrog Laboratory - Genopole's company

WatchFrog

WatchFrog markets in vivo biotechnological solutions for environmental risk assessment and the evaluation of the therapeutic, toxic or pollutant potential of all types of chemical, cosmetic or pharmaceutical compounds.

Discover
Pymabs - Genopole's Company

Pymabs

R & D services in the field of transient expression of recombinant proteins in plants.

Discover
Pharming - Genopole's company - Logo 2021

PHARMING

Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.

Discover
Glowee - Genopole's company

Glowee

Glowee is a cleantech startup developing a disruptive lighting technology based on bioluminescence (the natural light-producing property of certain living organisms).

Discover
Global Bioenergies - entreprise génopolitaine - logo 2022

Global Bioenergies

Global Bioenergies is developing a process to convert renewable resources into hydrocarbons through fermentation.

Discover
ABOLIS - entreprise génopolitaine

Abolis Biotechnologies

Abolis develops custom-order microorganisms able to produce molecules of interest via fermentation for the health, nutrition, chemistry and cosmetics sectors.

Discover
View all >
With the support from